SSG
MRNA icon

Summit Securities Group’s Moderna MRNA Stock Holding History

Summit Securities Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,000
Closed -$129K – 1160
2025
Q3 		$129K Buy
+5,000
New +$139K 0.03% 340
2023
Q4 		– Sell
-1,000
Closed -$103K – 819
2023
Q3 		$103K Hold
1,000
– – 0.01% 220
2023
Q2 		$122K Buy
+1,000
New +$133K 0.02% 266
2021
Q3 		– Sell
-10
Closed -$235K – 822
2021
Q2 		$235K Buy
+10
New +$1.79K 0.02% 613
2021
Q1 		– Sell
-185
Closed -$1.93M – 705
2020
Q4 		$1.93M Buy
+185
New +$18.7K 0.16% 148

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Summit Securities Group's MRNA Position: Q2 2026 in Review

Summit Securities Group reduced its Moderna (MRNA) stake by 95% in Q2 2026, selling an estimated $79.9K and leaving 82 shares worth $5.74K. The position accounts for ﹤0.01% of the portfolio, ranked #954.

Summit Securities Group first reported a position in MRNA in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.27M in Q4 2020. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Summit Securities Group held 82 shares of Moderna worth $5.74K as of Q2 2026.
  • Summit Securities Group sold 1,544 Moderna shares in Q2 2026, an estimated $79.9K.
  • Moderna made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #954 holding.
  • Summit Securities Group first reported a position in Moderna in Q4 2020 and has held it in 12 quarters since.
  • Summit Securities Group's Moderna position peaked at $1.27M in Q4 2020.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.